Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD); Healon Duet PRO II Dual Pack Sodium Hya
Johnson & Johnson Surgical Vision, Inc. · Decision date Oct 30, 2026
What did the FDA approve?
FDA records show supplement P810031/S083, tied to PMA P810031, was approved on 2026-10-30 for a design change. The supplied statement names the change as a new cannula design for the Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD).
The supplement scope is limited to use with that OVD in the individual pack and the Healon Duet PRO II Dual Pack. The source does not describe the cannula’s design details, any new indication, or any safety or effectiveness findings; it is a change/design supplement, not a new PMA for the whole system.
FDA approval order statement
approval for a new cannula design for use with the Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD) in both the individual pack and the Healon Duet PRO II Dual Pack
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Ophthalmic
- Decision date
- Oct 30, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P810031/S083
- Regulatory pathway
- PMA supplement
- Product code
- LZP
- Decision code
- APPR
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: AID, SURGICAL, VISCOELASTIC.
- Product code
- LZP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P810031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P810031 · Original PMA
HEALON, HEALON GV, HEALON5 PRODUCTS SODIUM HYALURONATE OPHTHALMIC VISCOELASTIC DEVICES
P810031/S083 received
Application receipt date recorded by FDA.
P810031/S083 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P810031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P810031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | PMA approval | Jan 14, 1983 | FDA |
Explore the linked device profile
Other records with product code LZP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Laboratories | PMA supplement | Oct 1, 2026 | FDA | |
PROVISC Ophthalmic Viscosurgical DeviceP890047/S072 | Alcon Research, Ltd. | PMA supplement | Oct 1, 2026 | FDA |
| Alcon Research, Ltd. | PMA approval | Sep 26, 1991 | FDA | |
| Alcon Laboratories | PMA approval | Apr 30, 1986 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Johnson & Johnson Surgical Vision, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P810031/S083
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



